Immunomodulation using placental stem cells
AssigneeAnthrogenesis Corporation
InventorsCasper Paludan, James Edinger, Ryhor Harbacheuski, RoseAnn Murray, Robert Hariri
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and cell populations.
Claims46
A method of suppressing an immune response comprising contacting a plurality of immune cells with a plurality of placental stem cells for a time sufficient for said placental stem cells to detectably suppress an immune response, wherein said placental stem cells detectably suppress T cell proliferation in a mixed lymphocyte reaction (MLR) assay.
A method of producing a placental cell population comprising
- (a) assaying a plurality of placental cells in a mixed lymphocyte reaction (MLR) assay;
- and
- (b) selecting said plurality of placental stem cells if said plurality of placental stem cells detectably suppresses CD4+ or CD8+ T cell proliferation in an MLR (mixed lymphocyte reaction), wherein said placental stem cells:
- (i) adhere to a substrate;
- and
- (ii) express CD200 and HLA-G, or
- express CD73, CD105, and CD200, or
- express CD200 and OCT-4, or
- express CD73, CD105, and HLA-G, or
- express CD73 and CD105, and facilitate the formation of one or more embryoid-like bodies in a population of placental cells that comprise the stem cell, when said population is cultured under conditions that allow formation of embryoid-like bodies, or
- express OCT-4, and facilitate the formation of one or more embryoid-like bodies in a population of placental cells that comprise the stem cell, when said population is cultured under conditions that allow formation of embryoid-like bodies.
An isolated population of placental stem cells, wherein said placental stem cells:
- (a) adhere to a substrate;
- (b) express CD200 and HLA-G, or
- express CD73, CD105, and CD200, or
- express CD200 and OCT-4, or
- express CD73, CD105, and HLA-G, or
- express CD73 and CD105, and facilitate the formation of one or more embryoid-like bodies in a population of placental cells that comprise the placental stem cells, when said population is cultured under conditions that allow formation of embryoid-like bodies, or
- express OCT-4 and facilitate the formation of one or more embryoid-like bodies in a population of placental cells that comprise the placental stem cells, when said population is cultured under conditions that allow formation of embryoid-like bodies;
- and
- (c) have been identified as detectably suppressing CD4+ or CD8+ T cell proliferation in an MLR.
A composition comprising culture medium from a culture of placental stem cells, wherein said placental stem cells
- (a) adhere to a substrate;
- (b) express CD200 and HLA-G, or
- express CD73, CD105, and CD200, or
- express CD200 and OCT-4, or
- express CD73, CD105, and HLA-G, or
- express CD73 and CD105, and facilitate the formation of one or more embryoid-like bodies in a population of placental cells that comprise the placental stem cells, when said population is cultured under conditions that allow formation of embryoid-like bodies, or
- express OCT-4 and facilitate the formation of one or more embryoid-like bodies in a population of placental cells that comprise the placental stem cells, when said population is cultured under conditions that allow formation of embryoid-like bodies;
- and
- (c) have been identified as detectably suppressing CD4+ or CD8+ T cell proliferation in an MLR,
- wherein said culture of placental stem cells has been cultured in said medium for 24 hours or more.
Dependencies are inferred from the claim text.